0001104659-22-001475.txt : 20220105 0001104659-22-001475.hdr.sgml : 20220105 20220105161555 ACCESSION NUMBER: 0001104659-22-001475 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jacobs John C CENTRAL INDEX KEY: 0001820836 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 22511324 MAIL ADDRESS: STREET 1: 630 W. GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 4 1 tm221863-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-01-03 0 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0001820836 Jacobs John C 630 W. GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING PA 19462 1 1 0 0 President, CEO Common Stock 2022-01-03 4 M 0 10647 8.22 A 10647 D Common Stock 2022-01-03 4 S 0 10647 45.1710 D 0 D Common Stock 2022-01-04 4 M 0 18053 8.22 A 18053 D Common Stock 2022-01-04 4 S 0 18053 45.1476 D 0 D Stock Option 8.22 2022-01-03 4 M 0 10647 0 D 2027-10-02 Common Stock 10647 252804 D Stock Option 8.22 2022-01-04 4 M 0 18053 0 D 2027-10-02 Common Stock 18053 234751 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.37. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.70. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is currently vested with respect to 251,801 shares, and will vest with respect to the remainder of the shares on October 1, 2022. /s/ Christian Ulrich, Attorney-in-fact 2022-01-05